News from the EMA, Cipla, and MethylGene – People on the move
The European Medicines Agency (EMA) has drafted in Enrica Alteri as head of safety and efficacy in the human medicines development and evaluation unit.
She joins the organisation from her role as head of risk management and epidemiology at Merck Serono.
Alteri is now required to declare her interests in the pharmaceutical industry and to cut all vested interests with pharma firms before she takes on the role.
Cipla has named Frank Pieters as the head of European region and the global respiratory business.
Yusuf K Hamied, chairman and managing director of the India pharma company, said: “This appointment signals Cipla’s strengthening of senior management positions and also illustrates Cipla’s desire for senior on-ground talent in overseas markets to build its product portfolio and brand.”
Pieters joins the firm from Teva Pharmaceuticals, where he was senior VP of Southern Europe.
MethylGene has placed Rodney Lappe onto its board of directors.
Lappe recently left his role at Pfizer’s CovX, where he was chief scientific officer, to join Tavistock.
Charles Grubsztajn, president and CEO of MethylGene said: "Dr. Lappe's background complements and enhances our Board, and we welcome his guidance as we advance the Company towards significant milestones."
Jonathan Jaffe has joined Antares Pharma as VP of clinical development.
Previously, he worked as a consultant for Pharmanet-i3 as a clinical program leader in inflammatory bowel disease.
Kaushik Dave, executive VP of product development, said: “Jonathan’s previous broad experience as a pharmaceutical clinician will be extremely valuable as we continue to execute on the development of our pipeline products.”
Graham Dixon is the new chief scientific officer and head of research for Addex Therapeutics .
Formerly the chief scientific officer for Galapagos NV, Dixon takes on the newly created position at Addex in a bid to drive R&D (research and development).
CEO Bharat Chowrira said: "Graham's experience and R&D leadership will be instrumental as we execute on our core strategy and continue to build a robust proprietary pipeline of high value drug discovery and development programs and rapidly advancing these drug candidates towards the clinic"
FluoroPharma Medical has named Thijs Spoor as chairman, replacing David Elmaleh who has handed in his resignation.
Spoor was previously chief financial officer for Sunstone BioSciences.
